# Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC

> **NCT05584137** · PHASE2 · TERMINATED · sponsor: **Shanghai Henlius Biotech** · enrollment: 2 (actual)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** HLX26
- **DRUG:** HLX10

## Key facts

- **NCT ID:** NCT05584137
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-15
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Due to poor clinical trial accrual, the study was terminated.
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05584137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05584137, "Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05584137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*